CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
Price achieved by oncology vs. non-oncology rare disease products by ASMR
CRA Life Sciences continues its series on leveraging RADAR, an orphan drug data repository. With rare oncology diseases in the spotlight at ASCO this season,...